Altimmune (ALT) Twitter Mentions Statistics 2025

110 37.5%

1W 11.3% 1M 72.1% 3M 83.5%

Est. daily mentions on Twitter.

Similar companies

Company		Twitter Mentions
	Amgen AMGN	57 11.8%
	Gilead Sciences GILD	40 81.8%
	Catalyst Pharmaceuticals CPRX	49
	Inovio Pharmaceuticals INO	41 115.8%
	Anavex Life Sciences AVXL	17 34.6%

Month over Month

Est. daily mentions on Twitter.

Sep 2025	138	61.8%
Aug 2025	362	74.6%
Jul 2025	1,423	99.1%
Jun 2025	715	301.9%
May 2025	178

How often is ALT mentioned on X?

The cashtag $ALT was mentioned an estimated 110 times in X posts yesterday.

Analyzing Twitter Mentions, how is Altimmune performing compared to its industry peers?

Altimmune underperforms its industry peers when it comes to Twitter Mentions, ranking in the 11th percentile.

Why is it important to track Twitter mentions for Altimmune?

By monitoring Twitter mentions for Altimmune, investors gain real-time insights into public sentiment towards the company, its products, and its industry. Positive mentions may indicate growing interest, customer satisfaction, or emerging trends, while negative mentions can alert investors to potential issues, controversies, or market challenges. By tracking these mentions over time, investors can identify patterns, spot emerging trends, and make informed decisions based on the evolving sentiment and public perception of Altimmune, ultimately improving their investment strategies.

About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.